Psychedelic News

  • Psyence Production Expands Capability

Psyence Production Expands Capability

2023-10-30T18:07:59+02:00October 30, 2023|Psychedelic News, Press Releases|

Psyence recently designed a new laboratory at the facility in order to expand its extraction capabilities. The building of the laboratory has since commenced and is expected to be completed in Q4 2023. The expansion fits under the existing building footprint, and once completed, new state-of-the-art extraction equipment will be installed to enhance its current extraction capabilities. There are multiple potential benefits to on-site extraction including increased product shelf life, a more stabilized format for export, and reduced transport costs.

  • PYSENCE_INGENU_FEATURE_2

Psyence Partners with iNGENū for Palliative Care Clinical Trial in Australia

2023-03-21T17:14:12+02:00March 21, 2023|Press Releases, Investor Information, Psychedelic News|

Psyence Australia Pty Ltd, has partnered with iNGENū Pty Ltd (iNGENū) to conduct Psyence’s previously announced clinical trial in palliative care. iNGENū is an Australian based, globally focused Contract Research Organization (CRO) with extensive experience working in the psychedelic pharmaceutical drug development and clinical research industry.

  • GOODMIND_FEATURE

GOODMIND Available For Sale In The United Kingdom And Europe – Exclusive Distribution Agreement Concluded With This Works.

2022-11-29T19:40:20+02:00November 29, 2022|Press Releases, Investor Information, Psychedelic News|

Psyence is pleased to announce that it has, together with its joint venture partner The Goodleaf Company (Pty) Ltd (“Goodleaf”), entered into an exclusive distribution agreement with This Works Products Limited (“This Works”) for the distribution and sale of the joint venture’s functional mushroom brand, GOODMINDTM, in the United Kingdom and Europe.

Go to Top